ADJUVANT/CTONG1104, a phase III study, compared adjuvant gefitinib directly with adjuvant vinorelbine plus cisplatin in patients with resected stage II–IIIA EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.